Mitochondria and the central nervous system: Searching for a pathophysiological basis of psychiatric disorders

Revista Brasileira de Psiquiatria

Volumn 36, Issue 2, 2014, Pages 156-167

  Streck, Emilio Luiz ^a,b,c   Gonçalves, Cinara L ^a,b,c   Furlanetto, Camila B ^a,b,c   Scaini, Giselli ^a,b,c   Dal Pizzol, Felipe ^a,b,c   Quevedo, João ^a,b,c  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b National Institute of Science and Technology in Translational Medicine (INCT TM)   (Brazil)

^c Center of Excellence in Applied Neuroscience of Santa Catarina (NENASC)   (Brazil)

Author keywords

Cell death; Central nervous system; Mitochondria; Neuroplasticity

Indexed keywords

4 AMINOBUTYRIC ACID; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BAG 1 PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 3; CASPASE 6; CASPASE 7; CYTOCHROME C OXIDASE; DOPAMINE; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GLUTAMIC ACID; GLUTATHIONE; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE; MONOAMINE OXIDASE INHIBITOR; NEUROTRANSMITTER; NEUROTROPHIC FACTOR; PROTEIN BAK; PROTEIN BAX; PROTEIN BID; REACTIVE OXYGEN METABOLITE; SEROTONIN; UNCOUPLING PROTEIN 2;

ANXIETY DISORDER; APOPTOSIS; ARTICLE; AUTISM; BIPOLAR DISORDER; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CENTRAL NERVOUS SYSTEM; COGNITION; DEPRESSION; DNA DAMAGE; ENERGY METABOLISM; ENZYME ACTIVITY; HUMAN; LONG TERM POTENTIATION; MENTAL DISEASE; MITOCHONDRION; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NERVOUS SYSTEM DEVELOPMENT; OBSESSIVE COMPULSIVE DISORDER; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION;

APOPTOSIS; CENTRAL NERVOUS SYSTEM; ENERGY METABOLISM; HUMANS; MENTAL DISORDERS; MITOCHONDRIA; MITOCHONDRIAL DISEASES;

EID: 84901196951     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/1516-4446-2013-1224     Document Type: Article

References (176)

1. Lenaz G, Genova ML. Structure and organization of mitochondrial respiratory complexes: a new understanding of an old subject. Antioxid Redox Signal. 2010;12:961-1008.
2. Alberts B. The cell as a collection of protein machines: preparing the next generation of molecular biologists. Cell. 1998;92: 291-4.
3. Pinton P, Giorgi C, Siviero R, Zecchini E, Rizzuto R. Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis. Oncogene. 2008;27:6407-18.
4. Ryan MT, Hoogenraad NJ. Mitochondrial-nuclear communications. Annu Rev Biochem. 2007;76:701-22.
5. Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron. 2008;60:748-66.
6. Herrero-Mendez A, Almeida A, Fernandez E, Maestre C, Moncada S, Bolanos JP. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat Cell Biol. 2009;11:747-52.
7. Brière JJ, Chrétien D, Bénit P, Rustin P. Respiratory chain defects: what do we know for sure about their consequences in vivo? Biochim Biophys Acta. 2004;1659:172-7.
8. Chang DT, Reynolds IJ. Differences in mitochondrial movement and morphology in young and mature primary cortical neurons in culture. Neuroscience. 2006;141:727-36.
9. Vayssière JL, Cordeau-Lossouarn L, Larcher JC, Basseville M, Gros F, Croizat B. Participation of the mitochondrial genome in the differentiation of neuroblastoma cells. In Vitro Cell Dev Biol. 1992;28A:763-72.
10. Chada SR, Hollenbeck PJ. Nerve growth factor signaling regulates motility and docking of axonal mitochondria. Curr Biol. 2004;14: 1272-6.
11. Li Z, Okamoto K, Hayashi Y, Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell. 2004;119:873-87.
12. Levy M, Faas GC, Saggau P, Craigen WJ, Sweatt JD. Mitochondrial regulation of synaptic plasticity in the hippocampus. J Biol Chem. 2003;278:17727-34.
13. Cheng A, Hou Y, Mattson MP. Mitochondria and neuroplasticity. ASN Neuro. 2010;2:e00045.
14. Cameron HA, Kaliszewski CK, Greer CA. Organization of mitochondria in olfactory bulb granule cell dendritic spines. Synapse. 1991;8:107-18.
15. Popov V, Medvedev NI, Davies HA, Stewart MG. Mitochondria form a filamentous reticular network in hippocampal dendrites but are present as discrete bodies in axons: a three-dimensional ultrastructural study. J Comp Neurol. 2005;492:50-5.
16. Zinsmaier KE, Babic M, Russo GJ. Mitochondrial transport dynamics in axons and dendrites. Results Probl Cell Differ. 2009;48:107-39.
17. Liesa M, Palacín M, Zorzano A. Mitochondrial dynamics in mammalian health and disease. Physiol Rev. 2009;89:799-845.
18. MacAskill AF, Atkin TA, Kittler JT. Mitochondrial trafficking and the provision of energy and calcium buffering at excitatory synapses. Eur J Neurosci. 2010;32:231-40.
19. Stowe DF, Camara AK. Mitochondrial reactive oxygen species production in excitable cells: modulators of mitochondrial and cell function. Antioxid Redox Signal. 2009;11:1373-414.
20. Williams JM, Thompson VL, Mason-Parker SE, Abraham WC, Tate WP. Synaptic activity-dependent modulation of mitochondrial gene expression in the rat hippocampus. Brain Res Mol Brain Res. 1998;60:50-6.
21. Calabresi P, Gubellini P, Picconi B, Centonze D, Pisani A, Bonsi P, et al. Inhibition of mitochondrial complex II induces a longterm potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J Neurosci. 2001;21: 5110-20.
22. Li Z, Jo J, Jia JM, Lo SC, Whitcomb DJ, Jiao S, et al. Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization. Cell. 2010;141:859-71.
23. Burkhalter J, Fiumelli H, Allaman I, Chatton JY, Martin JL. Brainderived neurotrophic factor stimulates energy metabolism in developing cortical neurons. J Neurosci. 2003;23:8212-20.
24. Markham A, Cameron I, Franklin P, Spedding M. BDNF increases rat brain mitochondrial respiratory coupling at complex I, but not complex II. Eur J Neurosci. 2004;20:1189-96.
25. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430:631-9.
26. Stefanis L. Caspase-dependent and-independent neuronal death: two distinct pathways to neuronal injury. Neuroscientist. 2005; 11:50-62.
27. Bender T, Martinou JC. Where killers meet-permeabilization of the outer mitochondrial membrane during apoptosis. Cold Spring Harb Perspect Biol. 2013;5:a011106.
28. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 2001;15:2922-33.
29. Penninger JM, Kroemer G. Mitochondria, AIF and caspases: rivaling for cell death execution. Nat Cell Biol. 2003;5:97-9.
30. Zamzami N, Kroemer G. Apoptosis: mitocondrial membrane permeabilization-the (w)hole story? Curr Biol. 2003;13:R71-3.
31. Cheung EC, Joza N, Steenaart NA, McClellan KA, Neuspiel M, McNamara S, et al. Dissociating the dual roles of apoptosisinducing factor in maintaining mitochondrial structure and apoptosis. EMBO J. 2006;25:4061-73.
32. Martins LM, Morrison A, Klupsch K, Fedele V, Moisoi N, Teismann P, et al. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol. 2004;24:9848-62.
33. Huang X, Zhai D, Huang Y. Dependence of permeability transition pore opening and cytochrome C release from mitochondria on mitochondria energetic status. Mol Cell Biochem. 2001;224:1-7.
34. Wang H, Yu SW, Koh DW, Lew J, Coombs C, Bowers W, et al. Apoptosis-inducing factor substitutes for caspase executioners in NMDA-triggered excitotoxic neuronal death. J Neurosci. 2004;24:10963-73.
35. Lu C, Wang Y, Furukawa K, Fu W, Ouyang X, Mattson MP. Evidence that caspase-1 is a negative regulator of AMPA receptormediated long-term potentiation at hippocampal synapses. J Neurochem. 2006;97:1104-10.
36. Gulyaeva NV, Kudryashov IE, Kudryashova IV. Caspase activity is essential for long-term potentiation. J Neurosci Res. 2003;73:853-64.
37. Massaad CA, Klann E. Reactive oxygen species in the regulation of synaptic plasticity and memory. Antioxid Redox Signal. 2011;14:2013-54.
38. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell. 2005;120:483-95.
39. Droge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82:47-95.
40. Boveris A, Oshino N, Chance B. The cellular production of hydrogen peroxide. Biochem J. 1972;128:617-30.
41. Barja G, Herrero AJ. Localization at complex I and mechanism of the higher free radical production of brain nonsynaptic mitochondria in the short-lived rat than in the longevous pigeon. J Bioenerg Biomembr. 1998;30:235-43.
42. Genova ML, Ventura B, Giuliano G, Bovina C, Formiggini G, Parenti Castelli G, et al. The site of production of superoxide radical in mitochondrial Complex I is not a bound ubisemiquinone but presumably iron-sulfur cluster N2. FEBS Lett. 2001;505:364-68.
43. Kushnareva Y, Murphy AN, Andreyev A. Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation-reduction state. Biochem J. 2002;368: 545-53.
44. Lesnefsky EJ, Gudz TI, Migita CT, Ikeda-Saito M, Hassan MO, Turkaly PJ, et al. Ischemic injury to mitochondrial electron transport in the aging heart: damage to the iron-sulfur protein subunit of electron transport complex III. Arch Biochem Biophys. 2001; 385:117-28.
45. St-Pierre J, Buckingham JA, Roebuck SJ, Brand MD. Topology of superoxide production from different sites in the mitochondrial electron transport chain. J Biol Chem. 2002;277:44784-90.
46. Beckman JS, Koppenol WH. Nitric oxide superoxide and peroxynitrite: the good the bad and the ugly. Am J Physiol. 1996;271: C1424-37.
47. Fridovich I. Superoxide radical and superoxide dismutases. Annu Rev Biochem. 1995;64:97-112.
48. Kishida KT, Klann E. Sources and targets of reactive oxygen species in synaptic plasticity and memory. Antioxid Redox Signal. 2007;9:233-44.
49. Gleichmann M, Mattson MP. Neuronal calcium homeostasis and dysregulation. Antioxid Redox Signal. 2011;14:1261-73.
50. Pinton P, Ferrari D, Magalhães P, Schulze-Osthoff K, Di Virgilio F, Pozzan T, et al. Reduced loading of intracellular Ca2+ stores and downregulation of capacitative Ca2+ influx in Bcl-2-overexpressing cells. J Cell Biol. 2000;148:857-62.
51. Pinton P, Ferrari D, Rapizzi E, Di Virgilio F, Pozzan T, Rizzuto R. The Ca2+ concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: significance for the molecular mechanism of Bcl-2 action. EMBO J. 2001;20:2690-701.
52. Palmer AE, Jin C, Reed JC, Tsien RY. Bcl-2-mediated alterations in endoplasmic reticulum Ca2+ analyzed with an improved genetically encoded fluorescent sensor. Proc Natl Acad Sci USA. 2004; 101:17404-9.
53. Foyouzi-Youssefi R, Arnaudeau S, Borner C, Kelley WL, Tschopp J, Lew DP, et al. Bcl-2 decreases the free Ca2+ concentration within the endoplasmic reticulum. Proc Natl Acad Sci USA. 2000;97:5723-8.
54. Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, Pozzan T, et al. BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science. 2003;300:135-9.
55. Duchen MR. Mitochondria, calcium-dependent neuronal death and neurodegenerative disease. Pflugers Arch. 2012;464:111-21.
56. Pardo B, Contreras L, Serrano A, Ramos M, Kobayashi K, Iijima M, et al. Essential role of aralar in the transduction of small Ca2+ signals to neuronal mitochondria. J Biol Chem. 2006;281:1039-47.
57. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol. 2003;4:552-65.
58. Choi DW. Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci Lett. 1985;58:293-7.
59. Nicholls DG. Mitochondrial calcium function and dysfunction in the central nervous system. Biochim Biophys Acta. 2009;1787: 1416-24.
60. Pivovarova NB, Andrews SB. Calcium-dependent mitochondrial function and dysfunction in neurons. FEBS J. 2010;277:3622-36.
61. Bano D, Young KW, Guerin CJ, Lefeuvre R, Rothwell NJ, Naldini L, et al. Cleavage of the plasma membrane Na+/Ca2+ exchanger in excitotoxicity. Cell. 2005;120:275-85.
62. Campanella M, de Jong AS, Lanke KW, Melchers WJ, Willems PH, Pinton P, et al. The coxsackievirus 2B protein suppresses apoptotic host cell responses by manipulating intracellular Ca2+ homeostasis. J Biol Chem. 2004;279:18440-50.
63. Chami M, Ferrari D, Nicotera P, Paterlini-Brechot P, Rizzuto R. Caspase-dependent alterations of Ca2+ signaling in the induction of apoptosis by hepatitis B virus X protein. J Biol Chem. 2003;278: 31745-55.
64. Jhons DR. The other human genome: mitochondrial DNA and disease. Nat Med. 1996;2:1065-8.
65. Schon EA, Manfredi G. Neuronal degeneration and mitochondrial dysfunction. J Clin Invest. 2003;111:303-12.
66. Shao L, Martin MV, Watson SJ, Schatzberg A, Akil H, Myers RM, et al. Mitochondrial involvement in psychiatric disorders. Ann Med. 2008;40:281-95.
67. Fattal O, Budur K, Vaughan AJ, Franco K. Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics. 2006;47:1-7.
68. Scaglia F. The role of mitochondrial dysfunction in psychiatric disease. Dev Disabil Res Rev. 2010;16:136-43.
69. Grover S, Padhy SK, DAS CP, Vasishta RK, Sharan P, Chakrabarti S. Mania as a first presentation in mitochondrial myopathy. Psychiatry Clin Neurosci. 2006;60:774-85.
70. Videbech P. PET measurements of brain glucose metabolism and blood flow in major depressive disorder: a critical review. Acta Psychiatr Scand. 2000;101:11-20.
71. Gardner A, Johansson A, Wibom R, Nennesmo I, von Döbeln U, Hagenfeldt L, et al. Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. J Affect Disord. 2003;76:55-68.
72. Magarinos AM, Deslandes A, Mcewen B. Effects of antide pressants and benzodiazepine treatments on the dendritic structure CA3 pyramidal neurons after chronic stress. Eur J Pharmacol. 1999;371:113-22.
73. Gardner A, Salmaso D, Nardo D, Micucci F, Nobili F, Sanchez-Crespo A, et al. Mitochondrial function is related to alterations at brain SPECT in depressed patients. CNS Spectr. 2008;13:805-14.
74. Madrigal JL, Olivenza R, Moro MA, Lizasoain I, Lorenzo P, Rodrigo J, et al. Glutathione depletion, lipid peroxidation and mitochondrial dysfunction are induced by chronic stress in rat brain. Neuropsychopharmacology. 2001;24:420-9.
75. Gamaro GD, Streck EL, MattéC, Prediger ME, Wyse AT, Dalmaz C. Reduction of hippocampal Na+, K+-ATPase activity in rats subjected to an experimental model of depression. Neurochem Res. 2003;28:1339-44.
76. Rezin GT, Cardoso MR, Gonçalves CL, Scaini G, Fraga DB, Riegel RE, et al. Inhibition of mitochondrial respiratory chain in brain of rats subjected to an experimental model of depression. Neurochem Int. 2008;53:395-400.
77. Rezin GT, Gonçalves CL, Daufenbach JF, Fraga DB, Santos PM, Ferreira GK, et al. Acute administration of ketamine reverses the inhibition of mitochondrial respiratory chain induced by chronic mild stress. Brain Res Bull. 2009;79:418-21.
78. Gong Y, Chai Y, Ding JH, Sun XL, Hu G. Chronic mild stress damages mitochondrial ultrastructure and function in mouse brain. Neurosci Lett. 2011;488:76-80.
79. Suomalainen A, Majander A, Haltia M, Somer H, Lönnqvist J, Savontaus ML, et al. Multiple deletions of mitochondrial DNA in several tissues of a patient with severe retarded depression and familial progressive external ophthalmoplegia. J Clin Invest. 1992;90:61-6.
80. Caetano SC, Olvera RL, Hatch JP, Sanches M, Chen HH, Nicoletti M, et al. Lower N-acetyl-aspartate levels in prefrontal cortices in pediatric bipolar disorder: a 1H magnetic resonance spectroscopy study. J Am Acad Child Adolesc Psychiatry. 2011;50:85-94.
81. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry. 2005;10:900-19.
82. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondriarelated genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet. 2005;14:241-53.
83. Munakata K, Iwamoto K, Bundo M, Kato T. Mitochondrial DNA 3243A. G mutation and increased expression of LARS2 gene in the brains of patients with bipolar disorder and schizophrenia. Biol Psychiatry. 2005;57:525-32.
84. Frey BN, Martins MR, Petronilho FC, Dal-Pizzol F, Quevedo J, Kapczinski F. Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disord. 2006;8:275-80.
85. Frey BN, Valvassori SS, Gomes KM, Martins MR, Dal-Pizzol F, Kapczinski F, et al. Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure. Brain Res. 2006;1097:224-9.
86. Frey BN, Valvassori SS, Réus GZ, Martins MR, Petronilho FC, Bardini K, et al. Effects of lithium and valproate on amphetamineinduced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci. 2006;31:326-32.
87. Corrêa C, Amboni G, Assis LC, Martins MR, Kapczinski F, Streck EL, et al. Effects of lithium and valproate on hippocampus citrate synthase activity in an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:887-91.
88. Streck EL, Amboni G, Scaini G, Di-Pietro PB, Rezin GT, Valvassori SS, et al. Brain creatine kinase activity in an animal model of mania. Life Sci. 2008;82:424-9.
89. Zugno AI, Valvassori SS, Scherer EB, Mattos C, MattéC, Ferreira CL, et al. Na+, K+-ATPase activity in an animal model of mania. J Neural Transm. 2009;116:431-6.
90. Valvassori SS, Rezin GT, Ferreira CL, Moretti M, Gonçalves CL, Cardoso MR, et al. Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with damphetamine. J Psychiatr Res. 2010;44:903-9.
91. Feier G, Valvassori SS, Varela RB, Resende WR, Bavaresco DV, Morais MO, et al. Lithium and valproate modulate energy metabolism in an animal model of mania induced by methamphetamine. Pharmacol Biochem Behav. 2013;103:589-96.
92. Bachmann RF, Wang Y, Yuan P, Zhou R, Li X, Alesci S, et al. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamineinduced mitochondrial damage. Int J Neuropsychopharmacol. 2009;12:805-22.
93. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322-6.
94. Bruckheimer EM, Cho SH, Sarkiss M, Hermann J, McDonnell TJ. The Bcl-2 gene family and apoptosis. Adv Biochem Eng Biotechnol. 1998;62:75-105.
95. Chen G, Henter ID, Manji HK. Translational research in bipolar disorder: emerging insights from genetically based models. Mol Psychiatry. 2010;15:883-95.
96. Kato T. Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications. CNS Drugs. 2007;21:1-11.
97. Kato T, Stine OC, McMahon FJ, Crowe RR. Increased levels of a mitochondrial DNA deletion in the brain of patients with bipolar disorder. Biol Psychiatry. 1997;42:871-5.
98. Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry. 2004;61:300-8.
99. MacDonald ML, Naydenov A, Chu M, Matzilevich D, Konradi C. Decrease in creatine kinase messenger RNA expression in the hippocampus and dorsolateral prefrontal cortex in bipolar disorder. Bipolar Disord. 2006;8:255-64.
100. Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron. 2003;38:157-60.
101. Duman RS. Pathophysiology of depression: the concept of synaptic plasticity. Eur Psychiatry. 2002;17:306-10.
102. Schweitzer N. Pegging pathology on mitochondrial dysfunction. Scientist. 2004;18:28.
103. Pivovarova NB, Pozzo-Miller LD, Hongpaisan J, Andrews SB. Correlated calcium uptake and release by mitochondria and endoplasmic reticulum of CA3 hippocampal dendrites after afferent synaptic stimulation. J Neurosci. 2002;22:10653-61.
104. Thiffault C, Quirion R, Poirier J. The effect of L-deprenyl, Ddeprenyl and MDL72974 on mitochondrial respiration: a possible mechanism leading to an adaptive increase in superoxide dismutase activity. Brain Res Mol Brain Res. 1997;49:127-36.
105. Aikey JL, Nyby JG, Anmuth DM, James PJ. Testosterone rapidly reduces anxiety in male house mice (Mus musculus). Horm Behav. 2002;42:448-60.
106. Bitran D, Foley M, Audette D, Leslie N, Frye CA. Activation of peripheral mitochondrial benzodiazepine receptors in the hippocampus stimulates allopregnanolone synthesis and produces anxiolytic-like effects in the rat. Psychopharmacology (Berl). 2000;151:64-71.
107. Horvat A, Nikezić G, Petrović S, Kanazir DT. Binding of estradiol to synaptosomal mitochondria: physiological significance. Cell Mol Life Sci. 2001;58:636-44.
108. Kaasik A, Safiulina D, Kalda A, Zharkovsky A. Dehydroepiandrosterone with other neurosteroids preserve neuronal mitochondria from calcium overload. J Steroid Biochem Mol Biol. 2003;87:97-103.
109. Morin C, Zini R, Simon N, Tillement JP. Dehydroepiandrosterone and alpha-estradiol limit the functional alterations of rat brain mitochondria submitted to different experimental stresses. Neuroscience. 2002;115:415-24.
110. Reddy DS, Kulkarni SK. Differential anxiolytic effects of neurosteroids in the mirrored chamber behavior test in mice. Brain Res. 1997;752:61-71.
111. Reddy DS, Kulkarni SK. Role of GABA-A and mitochondrial diazepam binding inhibitor receptors in the anti-stress activity of neurosteroids in mice. Psychopharmacology (Berl). 1996;128:280-92.
112. Murphy AN, Bredesen DE, Cortopassi G, Wang E, Fiskum G. Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Proc Natl Acad Sci USA. 1996;93:9893-8.
113. Einat H, Yuan P, Manji HK. Increased anxiety-like behaviors and mitochondrial dysfunction in mice with targeted mutation of the Bcl-2 gene: further support for the involvement of mitochondrial function in anxiety disorders. Behav Brain Res. 2005;165:172-80.
114. Torres AR, Lima MC. [Epidemiology of obsessive-compulsive disorder: a review]. Rev Bras Psiquiatr. 2005;27:237-42.
115. Inouye E. Similar and dissimilar manifestations of obsessivecompulsive neuroses in monozygotic twins. Am J Psychiatry. 1965;121:1171-5.
116. do Rosario-Campos MC, Leckman JF, Curi M, Quatrano S, Katsovitch L, Miguel EC, et al. A family study of early-onset obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet. 2005;136B:92-7.
117. Hanna GL, Himle JA, Curtis GC, Gillespie BW. A family study of obsessivecompulsive disorder with pediatric probands. Am J Med Genet B Neuropsychiatr Genet. 2005;134B:13-9.
118. van Grootheest DS, Cath DC, Beekman AT, Boomsma DI. Twin studies on obsessive-compulsive disorder: a review. Twin Res Hum Genet. 2005;8:450-8.
119. Pauls DL. The genetics of obsessive compulsive disorder: a review of the evidence. Am J Med Genet C Semin Med Genet. 2008;148C:133-9.
120. Kuloglu M, Atmaca M, Tezcan E, Gecici O, Tunckol H, Ustundag B. Antioxidant enzyme activities and malondialdehyde levels in patients with obsessive-compulsive disorder. Neuropsychobiology. 2002;46:27-32.
121. Selek S, Herken H, Bulut M, Ceylan MF, Celik H, Savas HA, et al. Oxidative imbalance in obsessive compulsive disorder patients: a total evaluation of oxidant-antioxidant status. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:487-91.
122. Chakraborty S, Dasgupta A, Das HN, Singh OP, Mandal AK, Mandal N. Study of oxidative stress in obsessive compulsive disorder in response to treatment with Fluoxetine. Indian J Clin Biochem. 2009;24:194-7.
123. Jesberger JA, Richardson JS. Oxygen free radicals and brain dysfunction. Int J Neurosci. 1991;57:1-17.
124. Weber GF. The pathophysiology of reactive oxygen intermediates in the central nervous system. Med Hypothesis. 1994;43:223-30.
125. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol. 2011;14:123-30.
126. Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK. Glutathione, iron and Parkinson's disease. Biochem Pharmacol. 2002;64:1037-48.
127. Dean OM, van den Buuse M, Bush AI, Copolov DL, Ng F, Dodd S, et al. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Curr Med Chem. 2009;16:2965-76.
128. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 1990;13:266-71.
129. Brambilla F, Bellodi L, Perna G, Arancio C, Bertani A. Dopamine function in obsessive compulsive disorder: growth hormone response to apomorphine stimulation. Biol Psychiatry. 1997;42: 889-97.
130. Lochner C, Hemmings SM, Kinnear CJ, Moolman-Smook JC, Corfield VA, Knowles JA, et al. Gender in obsessive-compulsive disorder: clinical and genetic findings. Eur Neuropsychopharmacol. 2004;14:105-13.
131. Labad J, Menchon JM, Alonso P, Segalas C, Jimenez S, Jaurrieta N, et al. Gender differences in obsessive-compulsive symptom dimensions. Depress Anxiety. 2008;25:832-8.
132. Wang Y, Samuels JF, Chang YC, Grados MA, Greenberg BD, Knowles JA, et al. Gender differences in genetic linkage and association on 11p15 in obsessive-compulsive disorder families. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:33-40.
133. Yamada S, Isojima Y, Yamatodani A, Nagai K. Uncoupling protein 2 influences dopamine secretion in PC12 cells. J Neurochem. 2003;87:461-9.
134. Duval C, Nègre-Salvayre A, Dogilo A, Salvayre R, Pénicaud L, Casteilla L. Increased reactive oxygen species production with antisense oligonucleotides directed against uncoupling protein 2 in murine endothelial cells. Biochem Cell Biol. 2002;80:757-64.
135. Walder K, Norman RA, Hanson RL, Schrauwen P, Neverova M, Jenkinson CP, et al. Association between uncoupling protein polymorphisms (UCP2-UCP3) and energy metabolism/obesity in Pima indians. Hum Mol Genet. 1998;7:1431-5.
136. de Bilbao F, Arsenijevic D, Vallet P, Hjelle OP, Ottersen OP, Bouras C, et al. Resistance to cerebral ischemic injury in UCP2 knockout mice: evidence for a role of UCP2 as a regulator of mitochondrial glutathione levels. J Neurochem. 2004;89:1283-92.
137. Calabrese V, Lodi R, Tonon C, D'Agata V, Sapienza M, Scapagnini G, et al. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J Neurol Sci. 2005;233: 145-62.
138. Lin Y, Han Y, Xu J, Cao L, Gao J, Xie N, et al. Mitochondrial DNA damage and the involvement of antioxidant defense and repair system in hippocampus of rats with chronic seizures. Cell Mol Neurobiol. 2010;30:947-54.
139. Mancuso C, Scapagini G, Currò D, Giuffrida Stella AM, De Marco C, Butterfield DA, et al. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci. 2007;12:1107-23.
140. Haas RH. Autism and mitochondrial disease. Dev Disabil Res Rev. 2010;16:144-53.
141. Palmieri L, Persico AM. Mitochondrial dysfunction in autism spectrum disorders: cause or effect? Biochim Biophys Acta. 2010;1797:1130-7.
142. El-Ansary A, Al-Ayadhi L. Neuroinflammation in autism spectrum disorders. J Neuroinflammation. 2012;9:265.
143. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57:67-81.
144. Singh VK. Plasma increase of interleukin-12 and interferon-gamma: pathological significance in autism. J Neuroimmunol. 1996;66: 143-5.
145. Croonenberghs J, Bosmans E, Deboutte D, Kenis G, Maes M. Activation of the inflammatory response system in autism. Neuropsychobiology. 2002;45:1-6.
146. Molloy CA, Morrow AL, Meinzen-Derr J, Schleifer K, Dienger K, ManningCourtney P, et al. Elevated cytokine levels in children with autism spectrum disorder. J Neuroimmunol. 2006;172: 198-205.
147. Ashwood P, Wakefield AJ. Immune activation of peripheral blood and mucosal CD3a lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J Neuroimmunol. 2006;173: 126-34.
148. Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007;22: 574-9.
149. El-Ansary A, Ben Bacha AG, Al-Ayadhi LY. Proinflammatory and proapoptotic markers in relation to mono and di-cations in plasma of autistic patients from Saudi Arabia. J Neuroinflammation. 2011;8:142.
150. Tostes MH, Teixeira HC, Gattaz WF, Brandão MA, Raposo NR. Altered neurotrophin, neuropeptide, cytokines and nitric oxide levels in autism. Pharmacopsychiatry. 2012;45:241-3.
151. Burchell VS, Gandhi S, Deas E, Wood NW, Abramov AY, Plun-Favreau H. Targeting mitochondrial dysfunction in neurodegenerative disease: Part II. Expert Opin Ther Targets. 2010;14: 497-511.
152. Serviddio G, Romano AD, Cassano T, Bellanti F, Altomare E, Vendemiale G. Principles and therapeutic relevance for targeting mitochondria in aging and neurodegenerative diseases. Curr Pharm Des. 2011;17:2036-55.
153. Camara AK, Lesnefsky EJ, Stowe DF. Potential therapeutic benefits of strategies directed to mitochondria. Antioxid Redox Signal. 2010;13:279-347.
154. Malkesman O, Austin DR, Tragon T, Henter ID, Reed JC, Pellecchia M, et al. Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants. Mol Psychiatry. 2012;17:770-80.
155. Hunsberger JG, Austin DR, Chen G, Manji HK. Cellular mechanisms underlying affective resiliency: the role of glucocorticoid receptor-and mitochondrially-mediated plasticity. Brain Res. 2009;1293:76-84.
156. Hunsberger JG, Austin DR, Chen G, Manji HK. MicroRNAs in mental health: from biological underpinnings to potential therapies. Neuromolecular Med. 2009;11:173-82.
157. Maeng S, Hunsberger JG, Pearson B, Yuan P, Wang Y, Wei Y, et al. BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments. Proc Natl Acad Sci USA. 2008;105:8766-71.
158. Hunsberger JG, Machado-Vieira R, Austin DR, Zarate C, Chuang DM, Chen G, et al. Bax inhibitor 1, a modulator of calcium homeostasis, confers affective resilience. Brain Res. 2011;1403: 19-27.
159. Zhu LP, Yu XD, Ling S, Brown RA, Kuo TH. Mitochondrial Ca(2+)homeostasis in the regulation of apoptotic and necrotic cell deaths. Cell Calcium. 2000;28:107-17.
160. Galeotti N, Bartolini A, Ghelardini C. Blockade of intracellular calcium release induces an antidepressant-like effect in the mouse forced swimming test. Neuropharmacology. 2006;50:309-16.
161. Galeotti N, Vivoli E, Norcini M, Bartolini A, Ghelardini C. An antidepressant behaviour in mice carrying a gene-specific InsP3R1, InsP3R2 and InsP3R3 protein knockdown. Neuropharmacology. 2008;55:1156-64.
162. Taragano FE, Allegri R, Vicario A, Bagnatti P, Lyketsos CG. A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of 'vascular depression'. Int J Geriatr Psychiatry. 2011;16:254-60.
163. Brunet G, Cerlich B, Robert P, Dumas S, Souetre E, Darcourt G. Open trial of a calcium antagonist, nimodipine, in acute mania. Clin Neuropharmacol. 1990;13:224-8.
164. Pazzaglia PJ, Post RM, Ketter TA, George MS, Marangell LB. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res. 1993;49:257-72.
165. Mogilnicka E, Czyrak A, Maj J. BAY K 8644 enhances immobility in the mouse behavioral despair test, an effect blocked by nifedipine. Eur J Pharmacol. 1988;151:307-11.
166. Kubota M, Kasahara T, Iwamoto K, Komori A, Ishiwata M, Miyauchi T, et al. Therapeutic implications of down-regulation of cyclophilin D in bipolar disorder. Int J Neuropsychopharmacol. 2010;13: 1355-68.
167. Pieper AA, Xie S, Capota E, Estill SJ, Zhong J, Long JM, et al. Discovery of a proneurogenic, neuroprotective chemical. Cell. 2010;142:39-51.
168. Stavrovskaya IG, Narayanan MV, Zhang W, Krasnikov BF, Heemskerk J, Young SS, et al. Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J Exp Med. 2004;200:211-22.
169. Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep. 2003;8:365-70.
170. Bakare A, Shao L, Cui J, Young LT, Wang JF. Mood stabilizing drugs lamotrigine and olanzapine increase expression and activity of glutathione S-transferase in primary cultured rat cerebral cortical cells. Neurosci Lett. 2009;455: 70-3.
171. Cui J, Shao L, Young LT, Wang JF. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience. 2007;144:1447-53.
172. Shao L, Cui J, Young LT, Wang JF. The effect of mood stabilizer lithium on expression and activity of glutathione s-transferase isoenzymes. Neuroscience. 2008;151:518-24.
173. Benrahmoune M, Thérond P, Abedinzadeh Z. The reaction of superoxide radical with N-acetylcysteine. Free Radic Biol Med. 2000;29:775-82.
174. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64:468-75.
175. Sies H, Stahl W, Sundquist AR. Antioxidant functions of vitamins. Vitamins E and C, beta-carotene, and other carotenoids. Ann NY Acad Sci. 1992;669:7-20.
176. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995;19:227-50.